Cargando…

Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey

INTRODUCTION: Patients with cancer and hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are underrepresented in several clinical trials testing immune checkpoint inhibitors (ICIs). Consequently, safety and efficacy of ICI therapy in this population have not been completely defined. We ai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tagliamento, Marco, Remon, Jordi, Giaj Levra, Matteo, De Maria, Andrea, Bironzo, Paolo, Besse, Benjamin, Novello, Silvia, Mezquita, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853354/ https://www.ncbi.nlm.nih.gov/pubmed/36687558 http://dx.doi.org/10.1016/j.jtocrr.2022.100446

Ejemplares similares

New emerging targets in cancer immunotherapy: the role of VISTA
por: Tagliamento, Marco, et al.
Publicado: (2020)

The efficacy of immune checkpoint inhibitors in thoracic malignancies
por: Remon, Jordi, et al.
Publicado: (2021)

Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review
por: Leone, Gianmarco, et al.
Publicado: (2020)

Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer
por: Duchemann, Boris, et al.
Publicado: (2020)

Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?
por: Hendriks, Lizza E. L., et al.
Publicado: (2021)

Epidemiology of oligometastatic non-small cell lung cancer: results from a systematic review and pooled analysis
por: Gobbini, Elisa, et al.
Publicado: (2021)

Advances and Therapeutic Perspectives in Extended-Stage Small-Cell Lung Cancer
por: Pierret, Thomas, et al.
Publicado: (2020)

Local for advanced, is this a paradox?
por: Bungaro, Maristella, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Opioids in Patients with Solid Tumours: Is Their Association Safe? A Systematic Literature Review
por: Cani, Massimiliano, et al.
Publicado: (2022)

Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options
por: Remon, Jordi, et al.
Publicado: (2016)

Immunotherapy in other thoracic malignancies and uncommon populations
por: Remon, Jordi, et al.
Publicado: (2021)

Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
por: Passiglia, Francesco, et al.
Publicado: (2021)

Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review
por: Naltet, Charles, et al.
Publicado: (2021)

Radon and Lung Cancer: Current Trends and Future Perspectives
por: Riudavets, Mariona, et al.
Publicado: (2022)

Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients
por: Jacobs, Francesca, et al.
Publicado: (2021)

Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
por: Remon, Jordi, et al.
Publicado: (2017)

Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
por: Remon, Jordi, et al.
Publicado: (2017)

Deciphering Lung Adenocarcinoma Heterogeneity: An Overview of Pathological and Clinical Features of Rare Subtypes
por: Mogavero, Andrea, et al.
Publicado: (2023)

Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
por: Inno, Alessandro, et al.
Publicado: (2023)

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform
por: Morfouace, M., et al.
Publicado: (2022)

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
por: Mazieres, J., et al.
Publicado: (2019)

Cystic brain metastases and RET fusion in lung cancer
por: Remon, Jordi, et al.
Publicado: (2020)

Repeated stereotactic radiosurgery for the treatment of relapsed brain metastases: is it time to give up whole-brain radiotherapy?
por: Nicosia, Luca, et al.
Publicado: (2020)

Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment
por: Remon, J., et al.
Publicado: (2018)

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives
por: Liu, Zherui, et al.
Publicado: (2023)

Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176
por: Auclin, Edouard, et al.
Publicado: (2021)

Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine
por: Pinsolle, Julian, et al.
Publicado: (2019)

1700P Perception and attitudes of Italian physicians towards the management of checkpoint inhibitors in oncology during COVID-19 outbreak: Results from a national survey
por: Tagliamento, M., et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
por: Reddy, Haritha G., et al.
Publicado: (2018)

Stereotactic radiosurgery for the treatment of brainstem metastases: a multicenter retrospective study
por: Nicosia, Luca, et al.
Publicado: (2022)

Exploring the immune-checkpoint inhibitors’ efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease
por: Passiglia, Francesco, et al.
Publicado: (2021)

Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report
por: Pluchart, Hélène, et al.
Publicado: (2017)

Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer
por: Gobbini, Elisa, et al.
Publicado: (2020)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

Management of rheumatic complications of immune checkpoint inhibitor therapy – an oncological perspective
por: Steven, Neil M, et al.
Publicado: (2019)

Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach
por: Bruni, Alessio, et al.
Publicado: (2019)

Altered splicing of ATG16‐L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non‐small cell lung cancer
por: Hatat, Anne‐Sophie, et al.
Publicado: (2022)

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images
por: Liberini, Virginia, et al.
Publicado: (2021)

Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma
por: Parent, Pauline, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7scu54bgv2plgu16ea7anb531r